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Abstract
The discovery of T cell epitopes is essential not only for gaining knowledge about host
response to infectious disease but also for the development of immune-intervention strate-
gies. In Chagas disease, given the size and complexity of the Trypanosoma cruzi proteome
and its interaction with the host’s immune system, the fine specificity of T cells has not been
extensively studied yet, and this is particularly true for the CD4+ T cell compartment. The
aim of the present work was to optimize a protocol for the generation of parasite-specific
memory T cell lines, representative of their in vivo precursor populations and capable of
responding to parasite antigens after long-term culture. Accordingly, peripheral blood mono-
nuclear cells (PBMC) from both chronic asymptomatic and cardiac patients, and from non-
infected individuals, underwent different in vitro culture and stimulation conditions.
Subsequently, cells were tested for their capacity to respond against T. cruzi lysate by mea-
suring [3H]-thymidine incorporation and interferon-γ and GM-CSF secretion. Results
allowed us to adjust initial T. cruzi lysate incubation time as well as the number of expan-
sions with phytohemagglutinin (PHA) and irradiated allogeneic PBMC prior to specificity
evaluation. Moreover, our data demonstrated that parasite specific T cells displayed a clear
and strong activation by using T. cruzi lysate pulsed, Epstein-Barr virus (EBV)-transformed
human B lymphocytes (B-LCL), as autologous antigen presenting cells. Under these culture
conditions, we generated a clone from an asymptomatic patient’s memory CD4+ T cells
which responded against epimastigote and trypomastigote protein lysate. Our results
describe a culture method for isolating T. cruzi specific T cell clones from patients with Cha-
gas disease, which enable the acquisition of information on functionality and specificity of
individual T cells.
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Introduction
Antigen specific CD4+ and CD8+ T cells are key components of the immune response devel-
oped by chronic patients infected with Trypanosoma cruzi, the causative agent of human Cha-
gas disease. Based upon observations in human infection and in experimental models, it is
currently accepted that T cells play an important role not only in controlling parasite burden
but also modulating disease progression [1–3]. During the chronic phase of the disease, in its
asymptomatic or cardiac manifestation forms, CD8+ T cells are believed to be involved in both
parasite control and in tissue damage, which contributes to cardiac alterations. This dual
action could be attributed to the existence of distinct populations of these cells that shift their
functional profile during the course of Chagas disease. In fact, asymptomatic patients have a
higher frequency of specific interferon-γ (IFN-γ) producing CD8+ T lymphocytes than people
with severe cardiac symptoms [1,4]. Furthermore, as a consequence of decades of low but con-
tinuous antigen exposure, in human T. cruzi infection, CD8+ T cells are driven to exhaustion,
leading to progressive impairment of their effector function [1,5–7].
On the other hand, CD4+ T cells and monocytes/macrophages participate in the secretion
of both inflammatory and anti-inflammatory cytokines, and this release correlates with the
clinical outcome of the disease [2,3]. In general, peripheral blood mononuclear cells (PBMC)
from cardiac chagasic patients produce more IFN-γ and less IL-10 than do those from asymp-
tomatic patients [8–10]. Accordingly, the majority of recombinant T. cruzi proteins or total
lysate induce a Th1 type cytokine profile (IFN-γ, TNF-α) with suppression of Th2 type cyto-
kines (IL-4, IL-10) in cardiac patients [11–18]. However, we recently demonstrated that this is
not true for the immune response developed by T. cruzi ribosomal P proteins, since the cyto-
kines released upon their stimulation made it difficult to determine a specific Th cell pheno-
type [18].
Although significant information has been obtained by studying activation markers and
cytokines secreted by CD4+ and CD8+ T cells during T. cruzi infection [3], knowledge about
the fine specificity of these cells is restricted to a few parasite epitopes. Most of these are pep-
tides from proteins belonging to the trans-sialidase family, like TS, ASP-1, ASP-2 [19–21].
Some other examples are comprised within the sequences of cruzipain, MASP, KPM-11, Tc24
or hypothetical proteins TcG1, TcG2 and TcG4 [22–27]. The study of T cell repertoire in pro-
tozoan parasitic infections is notably dissimilar from those of viruses and bacteria, in that their
large genomes and the complexity of their proteomes hamper the finding of relevant epitopes.
In the particular case of T. cruzi, its haploid genome encodes more than 12,000 genes [28], pro-
viding thousands of potential epitopes that could bind to the class I and class II major histo-
compatibility complex (MHC) molecules and be presented on the surface of infected host cells
or antigen presenting cells.
The study of pathogen specific human T cells is difficult due to their low frequency in
PBMC samples, approximately 1 in 105 cells in bulk cell population [29]. The potentially large
ratio of non-specific to specific cells, together with the protocol used for T cell expansion could
result in the selection of T cell populations different from the ones of interest in terms of speci-
ficity, phenotype or function. More importantly, the effects of extended long-term in vitro cul-
ture on T cell phenotype and function may therefore hinder the correlation of many T cell
clonal attributes with real in vivo characteristics [30].
As part of our ongoing studies to identify parasite epitopes recognized by human T cells in
the context of chronic Chagas disease, we decided to optimize the culture conditions of PBMC
from asymptomatic and cardiac patients in order to enable a maximum yield of T. cruzi-spe-
cific T cells. In the present work, we analyzed the effect of different time lengths of initial T.
cruzi lysate stimulation, the number of PHA expansions and the usefulness of Epstein-Barr
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virus (EBV)-transformed human B lymphocytes (B-LCL) as autologous antigen presenting
cells, in a small cohort of chagasic patients and non-infected donors. In addition, we generated
clones of memory CD4+ T cells from an asymptomatic patient that recognize the epimastigote
and trypomastigote/amastigote forms of the parasite.
Materials and methods
Ethics statement
The research followed the tenets of the Declaration of Helsinki and of the Medical Ethics Com-
mittee of the Hospital General de Agudos J.M. Ramos Mejia, which approved the protocols
used in this study. All enrolled patients were of age at the time the sample was taken, and they
gave written informed consent, according to the Hospital’s Ethics Committee guidelines,
before blood collection and after the nature of the study was explained.
Study population
Patient selection was conducted at the Cardiovascular Division of the Hospital General de
Agudos J.M. Ramos Mejia, Buenos Aires, Argentina. The study population consisted of 11
patients with positive serology for Chagas disease, determined by two or more tests (indirect
immunofluorescence, ELISA, indirect hemagglutination). The patients, in the chronic phase
of the infection, underwent a complete clinical and cardiological examination and were classi-
fied as asymptomatic (without demonstrable pathology) or cardiac patients. Five non-T. cruzi
infected individuals with negative serological tests for Chagas disease were included as the con-
trol group.
Parasite lysate
Whole antigenic lysate from T. cruzi epimastigote was prepared from axenic cultures (CL
Brenner strain) in LIT medium, as previously described [18]. After lysis, the suspension was
filter sterilized through a 0.2 μm pore-size membrane, aliquoted, and stored at -80˚C until use.
Trypomastigote/amastigote form lysate was similarly prepared and sterilized, from T. cruzi
Sylvio infected C2C12 cells (MOI 3:1) supernatants. Lysate composition was typically 52–54%
trypomastigotes, 46–48% amastigotes (percentages calculated on absolute parasites numbers).
PBMC isolation
PBMCs were obtained from whole blood by Ficoll-Hypaque density gradient centrifugation
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) according to manufacturer’s instructions,
less than 4 h after collection in EDTA-anticoagulated tubes. Cells were resuspended in T cell
medium (RPMI-1640 medium, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-gluta-
mine and 5% heat-inactivated male AB Rh-positive human serum (HS; Sigma, St Louis, MO,
USA)) and directly used in experiment, or in fetal calf serum (FCS; Natocor, Co´rdoba, Argen-
tina) containing 10% dimethylsulfoxide (DMSO), and cryopreserved in liquid nitrogen.
Generation and antigen priming of Epstein-Barr immortalized B cell lines
Autologous lymphoblastoid B cell lines (B-LCL) were generated for each patient, following an
adapted version of a protocol described elsewhere [31]. Briefly, Epstein-Barr virus (EBV) sus-
pension was prepared from B95.8 marmoset lymphoid cells culture supernatant, by centrifuga-
tion for 10 min at 300 ×g, 4˚C, and filtration through 0.45 μm pore size membrane filter. The
resulting virus-containing supernatants were preserved at -80˚C until use. For immortaliza-
tion, 107 PBMC were incubated with 1.25 ml of EBV suspension in a final volume of 5 ml LCL
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medium (RPMI-1640 supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM
L-glutamine and 10% FCS), for 2 h at 37˚C. Then, 5 ml of the same medium containing cyclo-
sporine A (Sigma, St Louis, MO, USA) at a final concentration of 1 μg/ml were added, and
incubation was continued for 3 weeks. Immortalization success was evaluated during this
period by monitoring cultures for cell clumps formation. After this, cells were characterized by
flow cytometry, using PE-Cy5-conjugated anti-CD19 and FITC-conjugated anti-CD3 antibod-
ies (BD Biosciences, San Diego, CA, USA.) Immortalized B cell lines (B-LCL) were further
expanded in LCL medium without cyclosporine A and cryopreserved in FCS with 10%
DMSO, in liquid nitrogen.
For antigen priming, B-LCL were cultured in low serum content LCL medium (RPMI
1640, 2% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine) at a density
of 0.5–1.0×106 cells/ml, for 24 h, then washed by centrifugation for 10 min at 400 ×g in 1.5 ml
PBS and incubated with 10 μg/ml T. cruzi lysate, either for 3 h or overnight, before irradiation.
PBMC stimulation and culture
For initial antigen stimulation, freshly isolated or cryopreserved PBMC from each subject were
seeded in 96-well U-bottom plates and cultured in T cell medium with 2.5 μg/ml T. cruzi lysate
(concentration was chosen based on titration experiments [18]). Non-specific stimulation with
5 μg/ml phytohaemagglutinin (PHA, Sigma, St Louis, MO, USA) was used as positive control
condition. The presence of clear signs of cellular proliferation (increase in the cell number and
clustering) was evaluated as evidence of normal physiological state of the cells at the beginning
of the culture process. Similarly, negative control wells were seeded and left unstimulated,
exhibiting no signs of cellular proliferation or activation.
Starting at indicated times after antigen stimulation, recombinant human interleukin-2
(IL-2; Peprotech, Mexico DF, Mexico) was added every 3 to 4 days at a final concentration of
50 IU/ml.
Memory CD4+ T cells separation, stimulation and culture
CD4+CD45RO+ T cells were isolated from PBMC using the immunomagnetic negative selec-
tion EasySep Human Memory CD4+ T Cell Enrichment Kit and Magnet (StemCell Technolo-
gies, Vancouver, Canada), following manufacturer provided indications. Recovery (40.9
±14.1%) and purity (93.6±1.2%) of the enriched population was assessed by flow cytometry,
staining with PE-Cy7 anti-CD4 (BioLegend, San Diego, CA, USA), FITC anti-CD3, PE-Cy5
anti-CD8, APC anti-CD45RA and PE anti-CD45RO (BD Biosciences, San Diego, CA, USA)
antibodies.
For initial stimulation, memory CD4+ T cells were seeded in 96-well plates, in T cell
medium, at 5×103 cells/well and incubated with 104 autologous irradiated PBMC and 2.5 μg/
ml T. cruzi epimastigote lysate, or at 103 cells/well and incubated with 104 allogeneic irradiated
PBMC from 3 non-related, non-infected donors, 1 μg/ml PHA and 50 IU/ml IL-2. This inter-
leukin was also added on every culture since day 3, every 3 to 4 days, at a final concentration of
50 IU/ml. Half the medium (100 μl/well) was refreshed every 10 to 14 days, beginning at day
15.
PHA expansion
For non-antigen specific expansion, cells were stimulated with 1.0 μg/ml PHA and 50 IU/ml
IL-2, in the presence of 2.5×104 irradiated (4,000 rads) allogeneic PBMC/well from 3 non-
infected, non-related donors. Control cultures were carried out in parallel by seeding 16–48
wells with irradiated allogeneic cells only.
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T. cruzi antigen specificity evaluation
Each culture was tested for their response to T. cruzi proteins in the presence of antigen pre-
senting cells (APC). Briefly, a fraction of the cells were transferred to a new 96-well plate and
cultured in T cell medium, with 2.5 μg/ml T. cruzi lysate or no antigen. As APC, irradiated
autologous PBMC (4,000 rads) or irradiated autologous, antigen-primed B-LCL (10,000 rads)
were used.
After 18 h, supernatants were collected for the quantification of IFN-γ and GM-CSF pro-
duction (OptEIA™ Human IFN-γ and Human GM-CSF ELISA sets, BD Pharmingen, San
Diego, CA, USA). Subtracted medium was replaced with T cell medium and cells were pulsed
for 24 h with 0.5 μCi/well [methyl-3H]-thymidine (Perkin Elmer, Waltham, MA, USA). Prolif-
eration was measured as incorporated radioactivity, assessed by liquid scintillation counting.
Limiting dilution assay (LDA)
T cells were plated in 96-well plates, at densities of 10, 3, 1 and 0.3 cells/well, and PHA expan-
sion was carried out, as described above. IL-2 was added every 3 to 4 days at 50 IU/ml. After 2
or 3 subsequent PHA expansions, spaced by 2 to 3 weeks and depending on cell growth, ali-
quots of these cultures were evaluated for T. cruzi antigens specificity. Based on this, parasite
specific cultures which grew to large enough numbers were characterized for TCR-Vβ expres-
sion by flow cytometry (see below).
TCR-Vβ flow cytometry staining
TCR-Vβ repertoire was analyzed by flow cytometry, using the IOTest Beta Mark Kit (Beck-
man-Coulter, USA) to stain 5×105 cells/tube, and following manufacturer’s instructions for
the staining protocol. CD3 and CD4 expression was also assessed for the same samples, as
described for memory CD4+ T cells.
Results
Impact of different culture conditions on the in vitro expansion and
functionality of parasite specific T cells
With the aim of expanding T. cruzi specific T cell populations from Chagas disease patients’
PBMC, different culture conditions were tested (Fig 1A).
Overall, the protocol consisted in an initial stimulation with T. cruzi lysate to selectively
amplify the cells of interest and subsequent expansions with PHA, IL-2 and irradiated alloge-
neic feeder cells to increase cell numbers. To assess the success of this procedure, cells were
challenged with T. cruzi lysate and the response was evaluated by two different readouts, IFN-γ
secretion and proliferation. Based on previous findings [18,32], we tested 6 days as initial stim-
ulation time in cultures from cardiac (RM11 and RM14) and asymptomatic (RM20) patients.
Two non-infected individuals (FI and MF) were included as controls. As shown in Fig 1B, cul-
tures from infected patients showed 43.9–53.8% positive wells, clearly suggesting the expan-
sion of parasite specific T cells. Under the same conditions, a substantial number of positive
wells were detected in cultures from non-infected individuals, in percentages ranging between
9.5–25.3% of the seeded wells (Fig 1B and 1C). However, the values obtained for the infected
subjects were significantly higher (S1 Table).
Given that the response detected in cultures from non-infected subjects could be associated
with undesired in vitro activation and amplification of naïve T cells, a following experiment
was carried out using a 1-day initial stimulation. This modification led to a reduction in the
percentage of positive wells from a non-infected donor’s cells (MM), but affecting the
Expansion of T. cruzi specific T cells from infected individuals
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Fig 1. Effect of initial stimulation time and PHA expansions on in vitro T cell response against T. cruzi lysate. PBMC were stimulated and expanded,
and aliquots of 1.0–2.0×104 T cells from these cultures were evaluated for T. cruzi antigens specificity, using 2.0–4.0×104 autologous irradiated PBMC as
APC. Response was measured as IFN-γ secretion and proliferation. Stimulatory index (SI) was calculated for each culture well as the response against T.
cruzi lysate divided by the cells baseline response (media only condition). Cultures considered positive were those with an SI2 (dotted line). Scatter plots
show individual well SI values. Bars represent the percentage of positive wells among the total wells analyzed for each subject. The numbers of positive vs
total studied wells is indicated above the bars. Color codes indicate which group each subject belongs to: chronic Chagas cardiopathy (red, subjects RM11,
RM14 and RM25), asymptomatic Chagas disease (blue, subjects RM20 and RM26) or non-infected (green, subjects FI, MF and MM). A. Timeline
representation of stimulation and specificity evaluations protocols. Numbers in brackets next to symbols indicate the day (or range of days, when slight
variations were required between subjects due to cell growth differences) since protocol start at which each step was performed. Numbers under the ‘initial
stimulation’ indicator (grey block) refer to the duration of the stimulus. B. Percentage of positive wells for at least one of the readouts in each subject’s
cultures when PBMC were initially stimulated for 6 days with T. cruzi lysate. IL-2 was added every 3–4 days since day 6 post initial stimulation. Specificity
evaluation was performed between days 64–71 after initial stimulation, and after 2 PHA expansions. C. Wells response by readout for each subject, in the
same experiment as B. D. T. cruzi-specific response in cultures derived from two Chagas disease patients and one non-infected subject. Cells were
stimulated with T. cruzi lysate for 1 day, and challenged at day 27 after one PHA expansion (“1st challenge”) or at day 47 after two PHA expansions (“2nd
challenge”). IL-2 was added since day 9, and every 3–4 days. E. Paired IFN-γ secretion and proliferation parasite-specific responses for each well, on 1st and
2nd challenges, from the same experiment as D. Values are expressed as SI. Statistical analysis for the percentages of positive wells shown in panels B and
C are detailed in S1 Table, and for panel D in S2 Table.
https://doi.org/10.1371/journal.pone.0178380.g001
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reactivity of cultures from asymptomatic patient RM26 and cardiac patient RM25 as well (Fig
1D). Overall, these results suggest that a shorter initial T. cruzi lysate stimulation period (1
day) leads to a lower in vitro activation of cell populations responsive to parasite antigens,
which could involve naïve, in vitro activated T cells, but also memory, specific T cells.
Aiming to address how PHA expansion cycles impacts on T. cruzi specific T cells enrich-
ment and their functional profile and capability, antigen specificity evaluations were per-
formed after 27 days of culture and 1 PHA expansion (“1st challenge”), or after 47 days of
culture and 2 PHA expansions (“2nd challenge”, Fig 1D and 1E). In terms of IFN-γ secretion,
specific response was observed only for the asymptomatic chronic Chagas patient RM26. For
this subject, as shown in Fig 1D, the percentage of positive wells increased after two rounds of
PHA expansion, but the overall SI levels were lower, as compared with the values obtained
after a single PHA expansion. On the other hand, a smaller percentage of proliferation positive
wells, but higher SI values, were observed for both chronic Chagas patients after two PHA
expansions. However, for the non-infected subject, positive wells rose from 2.0% after one
round, to 10.1% after two rounds of PHA expansion, suggesting that several non-antigen spe-
cific stimulations might favor the undesired amplification of T cells that are indeed not related
to infection.
Interestingly, many of the wells that responded on the 1st challenge became negative on the
2nd and vice versa, for both proliferation and IFN-γ secretion, as plotted on Fig 1E. No wells
switched from IFN-γ positive to proliferation positive, while 5.0% of the RM26 wells switched
from proliferation positive to IFN-γ positive. Of these, only 1.0% (on total seeded wells)
remained responsive by IFN-γ secretion while gaining proliferative responsiveness (data not
shown). Wells from neither the cardiac patient nor the non-infected individual exhibited this
behavior.
Overall, these results show that changing the conditions of the initial T. cruzi stimulation
and subsequent PHA expansion has an evident impact on the in vitro amplification of T. cruzi
specific cells. Furthermore, the data obtained with non-infected individuals indicate that there
is a significant and sizeable population of either naïve T cells, or memory T cells with a differ-
ent specificity, but cross-reactive to T. cruzi antigens, that can be expanded in vitro under these
culture conditions.
Autologous immortalized B-cells as antigen presenting cells of T. cruzi
lysate to T cell cultures
Due to the limited availability of patients’ PBMC, another important factor to consider when
developing T cell lines and clones for using in antigen discovery research is which cells are to
be used as antigen presenting cells. In order to assess the capability of autologous Epstein-Barr
virus-immortalized B cells (B-LCL) to present T. cruzi antigens in specificity evaluation experi-
ments, T cell culture protocols were carried out (Fig 2A), emulating stimulation and culture
conditions from experiments in Fig 1. To load the B-LCL, two different antigen priming con-
ditions were tested (3 h and overnight) by pre-incubating these cells with the lysate at a con-
centration of 10 μg/ml, prior to the challenge experiment.
Although the response was evaluated by IFN-γ secretion and proliferation, only the former
type of response was detectable upon challenge. As shown in Fig 2B, although pre-incubation
of the B-LCL with T. cruzi lysate induced IFN-γ secretion in T cell cultures from most subjects
studied, none of the cultures challenged with lysate primed-B-LCL reached the level of activa-
tion induced by irradiated PBMC as APC. However, the overnight priming condition pro-
duced SI values that enable a better detection of the response against the parasite lysate in
chronic Chagas patient cultures, as compared to the 3 h priming condition. Additionally, the
Expansion of T. cruzi specific T cells from infected individuals
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Fig 2. Use of autologous Epstein-Barr immortalized B-cells as antigen presenting cells. PBMC from
three cardiac patients, three asymptomatic patients and two non-infected individuals were seeded in two wells
of 96-well plates at 2×105 cells/well. Three different protocols (namely A, B and C) were used. IL-2 was added
every 3–4 days after the indicated time. At day 27 post-stimulation, cells from each condition were pooled and
2×103 T cells from each of these cultures were challenged with T. cruzi lysate or culture media only, using
autologous PBMC (4×103 cells/well), 3 h-antigen primed autologous B-LCL, or overnight-antigen primed
autologous B-LCL as APC (4×103 cells/well). A. Timeline representation of protocols A, B and C. Numbers in
brackets next to symbols indicate the day since protocol start at which each step was performed. Numbers
under the ‘initial stimulation’ indicator (grey blocks) refer to the duration of the stimulus. B. IFN-γ secretion
response as measured by ELISA. For each subject, stimulatory index (SI) was calculated as the response
Expansion of T. cruzi specific T cells from infected individuals
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quality of the response was higher in protocols B (1 day of antigen stimulation with IL-2 added
since day 9) and C (6 days of antigen stimulation with IL-2 added since day 6) when B-LCL
were used as APC. In conclusion, the results presented here demonstrate that overnight
primed B-LCL can be used as APC to present T. cruzi antigens to T cells.
Generation of T. cruzi specific memory CD4+ T cell lines from an
asymptomatic patient
Given the results presented above, we hypothesized that using enriched memory T cells,
instead of bulk PBMC, would favor the amplification of T cells that emerged in vivo, in
response to infection. Seeking to contribute to the scarce existing knowledge on the specificity
of memory CD4+ T cells in Chagas disease, we decided to focus our efforts on this population.
For this, CD3+CD4+CD45RO+ cells from an asymptomatic chronic Chagas patient (RM30)
and a non-infected individual (MM) were magnetically sorted from PBMC samples, and ini-
tially cultured with two different stimuli: T. cruzi lysate with irradiated autologous PBMC as
APC (antigen specific, selective expansion) or PHA, IL-2 and irradiated allogeneic PBMC as
feeder cells (non-antigen specific, non-selective expansion). An overview of the protocols used
is represented in Fig 3A. The stimulation of cells from both subjects with PHA resulted in a
clear growth of all the seeded wells (Fig 3B). In contrast, the percentages of wells that grew in
response to T. cruzi lysate was lower and significantly different between subjects (58.3% for
RM30 vs 12.4% for MM, Fisher’s exact test, p<0.001, Fig 3C).
After the initial expansion, specificity was assessed for these cultures using overnight anti-
gen primed autologous B-LCL as APC. Most of RM30 wells initially stimulated with parasite
lysate responded against T. cruzi antigens (73.2% for IFN-γ secretion, 17.9% for proliferation,
Fig 3C and 3E) in contrast to the remarkably lower number found in wells initially expanded
with PHA (25.0% for IFN-γ, 4.2% for proliferation, Fig 3B and 3D). On the other hand, 21.0%
of the lysate expanded wells (only 1.53% out of the total seeded wells) from the non-infected
subject responded by IFN-γ secretion, and none responded by proliferation (Fig 3B and 3D).
Fisher’s exact test was applied to analyze the difference in frequencies of wells responding, by
at least one of the readouts, between the infected and the non-infected donors, and a statistical
significance was observed under both initial stimulation conditions, T. cruzi lysate (p = 0.0003)
and PHA (p = 0.02). Furthermore, the IFN-γ secretion levels measured in cultures initially
expanded with T. cruzi lysate were significantly higher for the chronic Chagas patient as com-
pared to those from the non-infected individual’s cultures (p<0.01, Mann-Whitney test).
Several T cell lines were generated from cultures detected as parasite-specific, and they were
further expanded and re-tested for specificity, as previously described. As shown in Fig 4, lines
originated from cultures initially stimulated with T. cruzi maintained their responsiveness
against parasite lysate by IFN-γ secretion, while those expanded from cells stimulated with
PHA did not. Moreover, response by proliferation was no longer observed at this point, even
from T cell lines RM30.I and RM30.II, which had been positive for this readout on previous
specificity evaluations. In order to avoid limiting the evaluation of specificity only to the quan-
tification of IFN-γ, a multiplex cytokine detection assay (MesoScale Discovery, San Diego,
CA) was performed on selected supernatants from experiment shown in Fig 3. A panel of 8
inflammatory and regulatory cytokines (IL-2, IL-4, IL-10, IL-13, IL-17a, TNF-α, GM-CSF,
against T. cruzi lysate divided by the cells baseline response (media only condition), each dot represents
mean SI value of three biological replicates for a single subject. Dashed lines link values belonging to the
same subjects. Bars represent mean SI value for each group. Color codes indicate which group each subject
belongs to: chronic Chagas cardiopathy (red), asymptomatic Chagas disease (blue) or non-infected (green).
https://doi.org/10.1371/journal.pone.0178380.g002
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Fig 3. Effect of stimulus used for initial expansion of antigen specific memory CD4+ T cells and their in vitro
response against T. cruzi antigens. Sorted memory CD4+ T cells from an asymptomatic Chagas patient (RM30) and a
non-infected subject (MM) were stimulated with PHA (B, D) or parasite lysate (C, E) as detailed under Materials and
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IFN-γ) was evaluated. Results from these experiments pinpointed IFN-γ and GM-CSF as the
most reliable readouts for T. cruzi CD4+ T cell specificity (data not shown).
In summary, these results confirm the advantages of an initial stimulation with the parasite
lysate on memory CD4+ T cells obtained from chronic Chagas patients, both in terms of
expansion capability and selectivity.
Generation of T. cruzi specific memory CD4+ T cell clones
In order to isolate an antigen-specific clonal population from the T cell lines generated as
described above, we used line RM30.II from the previous section to set up a limiting dilution
assay (LDA) using 4 different cell density conditions (10, 3, 1 and 0.3 cells/well), in 10 U-bot-
tom 96-well plates for each condition. Of note, RM30.II was selected for this process based on
its growth rate, besides the observed specific response. Cells were expanded with PHA 7 times
(except for the 10 cells/well condition, which were expanded 5 times), and specificity evalua-
tions were performed, measuring IFN-γ and GM-CSF secretion, as detailed on S1 Fig. Using
growth rate and specificity as criteria, several T. cruzi-specific cultures were selected. On day
99 after the LDA start, all of these cultures showed a clear parasite-specific response (Fig 5A).
In addition, T cell lines RM30.II.84 and .85 were tested for specificity against epimastigote
and trypomastigote/amastigote lysate. As shown in Fig 5B, line RM30.II.84 responded specifi-
cally to both parasite forms. Seeking to assess whether this line was monoclonal, we performed
a TCR-Vβ repertoire characterization by flow cytometry. Results showed these cells exclusively
Methods. Five thousand cells from each culture well were challenged between days 27–32 (depending on cell growth) with
parasite lysate or culture media only and the antigen-specific response was measured as IFN-γ secretion and proliferation.
Ten thousand autologous overnight-primed B-LCL per well were used as APC. SI was calculated for each well as the
response against T. cruzi lysate divided by the cells baseline response (media only condition). Statistical analysis of the
percentage of positive wells is shown in S3 Table. A. Timeline representation of stimulation and challenge protocols.
Numbers in brackets next to symbols indicate the day (or range of days) since protocol start at which each step was
performed. B, C. Pie chart representations of the wells that showed cell growth after initial stimulation, and different
degrees of antigen specific response against T. cruzi lysate. D, E. SI values (scatter plots) and percentage of positive wells
(bars) for each readout. Cultures considered positive were those with an SI2 (dotted line). Positive and total studied wells
are indicated in numbers above the bars.
https://doi.org/10.1371/journal.pone.0178380.g003
Fig 4. Antigen specific response in selected cultures from subject RM30. Cell lines were established from T. cruzi specific cultures, based on
results from experiment depicted on Fig 3. Cells were submitted to 2 PHA expansion cycles prior to specificity evaluation. Five thousand cells from
each culture well were challenged with T. cruzi lysate, using 104 autologous overnight-primed B-LCL per well as APC. SI was calculated for each
well as the response against T. cruzi lysate divided by the cells baseline response (media only condition), cultures considered positive were those
with an SI2 (dotted line). Bars show the mean values and standard deviation for three replicates of each measure.
https://doi.org/10.1371/journal.pone.0178380.g004
Expansion of T. cruzi specific T cells from infected individuals
PLOS ONE | https://doi.org/10.1371/journal.pone.0178380 May 26, 2017 11 / 19
express a TCR from the Vβ 5.2 family, demonstrating RM30.II.84 is a clonal T cell line
(Table 1).
Discussion
It is known that the in vitro expansion of lymphocytes collected from peripheral blood mono-
nuclear cells (PBMC) could modify the ex vivo phenotype and function of CD4+ and CD8+ T
cells, which in part, could be reflected in the loss of antigen specific memory subsets, changes
in specificity and the acquisition of late effector or exhausted phenotypes over time [33–36].
Fig 5. Antigen specific response in cultures resulting from limiting dilution assay (LDA) of culture RM30.II. A. Twenty-five thousand cells
from each culture well were challenged with T. cruzi lysate, using 5×104 autologous overnight-primed B-LCL per well as APC. Specificity against T.
cruzi antigens was assessed for several potentially monoclonal lines by IFN-γ and GM-CSF secretion. N/A: Non applicable. B. Specific response
was tested using lysates from different stages in the parasite’s life cycle (epimastigote and trypomastigote/amastigote) for T cell lines RM30.II.84
and .85.
https://doi.org/10.1371/journal.pone.0178380.g005
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Here, we generated enriched T. cruzi specific T cell lines after an initial PBMC stimulation
with parasite lysate. The frequency of T. cruzi responsive cell cultures was greater in asymp-
tomatic and cardiac patients than in non-infected individuals, and it increased in a stimulation
time dependent manner. Noticeably, when statistical analysis was applied population-wise to
each subject’s cultures, only T cells from Chagas disease patients showed a significantly higher
response against T. cruzi lysate, as compared to the baseline response. Conversely, non-
infected individuals exhibited either no response, or response inhibition induced by the para-
sitic antigens (S2 and S3 Figs). However, when bulk PBMC were used to generate the libraries,
some of the T cell cultures expanded from non-infected donors’ samples were responsive to T.
cruzi. This response, provoked by whole parasite lysate, could be the result of: 1) lectins or
superantigens, which could induce a polyclonal, non-specific activation; 2) an antigen-specific
primary response from naïve T cells, or 3) memory T cells being specific for host or other path-
ogens epitopes, and cross-reactive to T. cruzi antigens. In this regard, Piuvezam et al (1993)
demonstrated that short term T cell lines generated against T. cruzi from healthy donors
PBMC were predominantly memory cells and proliferative response was MHC dependent,
suggesting that parasite lysate contains epitopes that cross-react with other antigens of envi-
ronmental origin, and ruling out a potential involvement of lectins or superantigens as non-
specific mitogens [37]. Seeking to minimize the potential contribution of naïve T. cruzi reac-
tive T cells expansion, we undertook our subsequent experiments with enriched memory T
cells instead of whole PBMC. Our observation of a certain degree of reactivity in memory
CD4+ T cells from a non-infected subject favors the hypothesis of cross-reactivity, meaning
Table 1. Detected frequencies of TCR-Vβ families expressed on T cells from lines RM30.II and RM30.
II.84.
TCR-Vβ family RM30.II RM30.II.84
1 0.00 0.02
2 0.16 0.02
3 0.00 0.00
4 0.00 0.01
5.1 0.39 0.03
5.2 0.28 0.92
5.3 0.02 0.00
7.1 0.00 0.02
7.2 0.00 0.02
8 0.00 0.00
9 0.00 0.00
11 0.06 0.01
12 0.00 0.00
13.1 0.03 0.04
13.2 0.00 0.00
13.6 0.00 0.01
14 0.00 0.00
16 0.00 0.00
17 0.00 0.01
18 0.00 0.01
20 0.04 0.00
21.3 0.01 0.02
22 0.00 0.02
23 0.00 0.00
https://doi.org/10.1371/journal.pone.0178380.t001
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these cells have most probably been selected in vivo at the setup of an adaptive response to
non-T. cruzi related agents, and cross-react against T. cruzi epitopes. It is also likely that they
would be activated early in the context of a first exposure of this subject to the parasite, which
makes their specificity an interesting subject for further studies. Nevertheless, under our exper-
imental conditions, the frequency and reactivity of such parasite-responsive cultures were
remarkably lower than in those derived from a Chagas disease patient, reinforcing the reliabil-
ity of our approach.
Another important conclusion drawn from our results lies on the fact that, for memory
CD4+ T cell cultures, initially stimulated with T. cruzi lysate, the proportion of wells exhibiting
cellular growth was dramatically higher in the chagasic patient RM30 as compared to the non-
infected individual MM. On the contrary, when PHA was the initial stimulus, cell growth was
observed across all the culture wells, from both subjects. Furthermore, initial stimulation of
the Chagas disease patient’s cells with parasite lysate rendered not only a greater proportion of
parasite-reactive wells, but also higher specific response values. On that regard, Geiger et al.
(2009) demonstrated that within the memory compartment, polyclonal PHA stimulation of
CD4+ T cells allows the expansion of T cells specific for recall antigens from tetanus, CMV and
M. tuberculosis, at high frequencies [38]. However, even though we were able to reproduce this
phenomenon with cells from Chagas disease patients, our results highlight the role of a single
initial in vitro stimulation with parasite proteins to increase the frequency at which specific cul-
tures were detected, enabling the subsequent expansion and characterization of pathogen-spe-
cific T cells. Several other reported protocols using a specific antigen or its peptides as initial
stimulus support our finding [39, 40].
To yield an appropriate quantity of specific T cells, another important step is the expansion
of the cultures. Our results showed that, when starting with bulk PBMC, two rounds of non-
specific re-stimulation with PHA could increase the number of naïve/cross-reactive T cells not
related to infection, as shown by the proliferation response rendered by T cells derived from
non-infected individuals. In addition, each round affected the specificity of the cell popula-
tions. This dynamic change in antigen specificity could also be associated with a direct effect of
the mitogen over the functional characteristics of T cells [41], or be the consequence of the
enrichment of certain T cells in the well, leading to gain or loss in frequency of parasite specific
T cells. The same phenomenon was observed in T cell lines RM30.IV and .V, which came from
a chronic asymptomatic Chagas patient enriched memory CD4+ T cells with a non-specific
initial stimulus. However, the specificity of lines RM30.I, .II and .III, which were generated by
antigen-specific stimulation of the same T cell subset seems to be long-term stable, regardless
of the number of subsequent PHA expansions.
An interesting finding of the present study lies in the use of T. cruzi primed B-LCL to func-
tion as antigen-presenting cells (APCs) for the assessment of T cell responses. Although autol-
ogous PBMC or dendritic cells are a better source of the so called “professional” APC, their
usage relies on repeated blood donations [42]. In contrast, although B-LCL have less capacity
to present soluble antigens compared to monocytes or dendritic cells, they are a sustainable
and scalable source of APC. In fact, immortalized B-LCL have been broadly used with success
in different protocols that require in vitro antigen presentation to T cells. However, no data
were available about their use as APC for the presentation of T. cruzi proteins. Here, our results
showed that both PBMC and overnight parasite lysate-pulsed B-LCL induced similar IFN-γ
secretion profiles in T cells from asymptomatic and cardiac patients.
After LDA, T cell lines generated from memory CD4+ T cells from a chagasic patient and
maintained under the described culture conditions, retained their specific response capability
towards T. cruzi lysate for more than 98 days. Moreover, T cell line RM30.II.84 responded
against epimastigote and trypomastigote/amastigote lysate with similar strength, indicating
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that these cells recognize a common epitope expressed in both non-infective and infective par-
asite forms. Finally, TCR-Vβ analysis demonstrated a prevalence of TCR-Vβ 2, 5.1 and 5.2
families in memory CD4+ T cell line RM30.II while its derived clone RM30.II.84 expresses
TCR-Vβ 5.2.
Even though the generality of our findings is limited due to the small number of subjects
(patients and non-infected donors) included throughout the study, it is possible to ascertain a
suitable protocol for the generation of specific oligo- and monoclonal T cell lines from patients
with Chagas disease. Although our first efforts were focused on the generation of memory
CD4+ T cell clones from an asymptomatic subject, we expect that this method will be useful
for the expansion of T. cruzi specific T cells from cardiac patients. However, it could represent
a greater challenge, due to the higher frequency of CD4+ T cells with senescent and exhausted
phenotype in the peripheral blood of these patients as compared to asymptomatic ones [43].
We speculate that it will not be possible to obtain as many detectable specific T cell lines per
patient as we have for asymptomatic patients assayed so far, or that it will be more difficult to
amplify them to numbers large enough. Hoping to shed some light in this issue, we are cur-
rently looking into the ex vivo expression profiles of several inhibitory receptors which have
been associated to T cell exhaustion [44], and how they vary during in vitro culture and
expansion.
In conclusion, our data demonstrate that: 1) starting the expansion from enriched memory
T cells instead of PBMC allow the increase of the stimulation time, enabling the selection of a
larger number of parasite specific T cell cultures; 2) an antigen specific initial stimulation is
beneficial for the ex vivo selective expansion of pathogen related memory CD4+ T cell popula-
tions, as compared with a non-antigen specific, although stronger, stimulation (as PHA); 3)
the use of different readouts, in this particular case IFN-γ and GM-CSF secretion, is important
in order to detect the largest number of antigen-specific positive wells and 4) B-LCL primed
with T. cruzi lysate by an overnight incubation are capable to perform antigen presentation
and stimulate parasite specific T cells. This work constitutes the first step in our ongoing T cell
driven approach to the identification of human immunogenic T. cruzi epitopes, a matter of
key relevance for the understanding of the immune response in Chagas disease.
Supporting information
S1 Fig. Schematic representation of the LDA protocol. T cells were plated in 96-well plates,
at densities of 10, 3, 1 and 0.3 cells/well (rows), and submitted to PHA expansion. Numbers
indicate the amount of wells that were expanded each time (columns), after the previous
round of selection, according to the criteria indicated by arrows.
(EPS)
S2 Fig. IFN-γ secretion raw values for specificity experiments on T cells derived from
PBMC. For each challenge experiment on Fig 1, paired results for each culture were statisti-
cally analyzed using Wilcoxon’s signed rank test. (/#: p<0.05; /##: p<0.01; /###:
p<0.001; /####: p<0.0001). Asterisks show statistical significance in cases were the T. cruzi
lysate challenged response was significantly higher than the one from the culture medium only
condition (W>0). Similarly, number signs show significance in the cases in which the baseline
response was significantly higher than the one from the lysate challenged aliquots (W<0).
Color codes indicate which group each subject belongs to: chronic Chagas cardiopathy (red),
asymptomatic Chagas disease (blue) or non-infected (green). NA: No antigen condition; Tc: T.
cruzi lysate. A. Results from experiment explained in Fig 1B and 1C. B. Results from experi-
ment explained in Fig 1D.
(PDF)
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S3 Fig. Proliferation raw values for specificity experiments on T cells derived from PBMC.
For each challenge experiment on Fig 1, paired results for each culture were statistically ana-
lyzed using Wilcoxon’s signed rank test. (/#: p<0.05; /##: p<0.01; /###: p<0.001;
/####: p<0.0001) Asterisks show statistical significance in cases were the T. cruzi lysate
challenged response was significantly higher than the one from the culture medium only con-
dition (W>0). Similarly, number signs show significance in the cases in which the baseline
response was significantly higher than the one from the lysate challenged aliquots (W<0).
Color codes indicate which group each subject belongs to: chronic Chagas cardiopathy (red),
asymptomatic Chagas disease (blue) or non-infected (green). NA: No antigen condition; Tc: T.
cruzi lysate. A. Results from experiment explained in Fig 1B and 1C. B. Results from experi-
ment explained in Fig 1D.
(PDF)
S1 Table. Statistical analysis for the effect of 6 days stimulation with parasite lysate on
PBMC. The numbers correspond to Fisher’s exact tests p values with Bonferroni-Holm correc-
tion for multiple comparisons applied to the analysis of the percentage of positive wells. Data
from two non-infected subjects (FI and MF) was pooled for comparison with each infected
subject, see Fig 1B and 1C. p<0.05 was considered statistically significant.
(DOCX)
S2 Table. Statistical analysis for the effect of PHA expansions on T. cruzi specific T cell
response. The numbers correspond to p values of Fisher’s exact tests with Bonferroni-Holm
correction applied to the percentage of positive wells from each patient in comparison with
non-infected subject, named MM, see Fig 1D and 1E. p<0.05 was considered significantly.
(DOCX)
S3 Table. Statistical analysis for the effect of initial stimulus on memory CD4+ T cells. The
numbers correspond to p values of Fisher’s exact tests with Bonferroni-Holm correction
applied to the percentage of positive wells from the patient in comparison with non-infected
subject, named MM, see Fig 3. p<0.05 was considered significantly.
(DOCX)
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